AstraZeneca inked a deal just at the end of October with Swiss contract manufacturer Lonza to produce AZD7442, a combination of two long-acting antibodies (LAABs) for the potential prevention and treatment of COVID-19. The actual antibodies were discovered by Vanderbilt University Medical Center and thereafter licensed to AstraZeneca in June. What is this investigational therapy and how will the two companies work together?
TrialSite News offers a brief breakdown of this partnership and the underlying investigational therapy.
What is AZD7442?
Discovered by researchers at Vanderbilt University Medical Center, they and AstraZeneca entered into a licensing deal back on June 20th. Now known as AZD7442, this combination of two LAABs was derived from convalescent patients after SARS-CoV-2 infection. The LAABs were optimized by AstraZeneca with half-life extension and reduced Fc receptor binding. The half-life extended LAABs may afford six to 12 months of protection from COVID-19. The reduced Fc receptor binding aims to minimize the risk of antibody-dependent enhancement of disease—a phenomenon in which virus-specific antibodies promote, rather than inhibit, infection and/...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).